Medical Hemostatic Agents

Medical Hemostatic Agents Market Outlook

The global medical hemostatic agents market was valued at approximately USD 3.5 billion in 2022 and is projected to reach around USD 5.6 billion by 2035, growing at a CAGR of about 4.5% during the forecast period. This growth can be attributed to increasing surgical procedures worldwide, a rise in trauma cases, and the growing prevalence of chronic diseases that necessitate surgical interventions. Additionally, advancements in medical technologies and the continuous development of innovative hemostatic agents have significantly contributed to market expansion. The growing focus on patient safety and effective management of bleeding during surgeries is further driving the demand for these agents, offering immense growth opportunities for manufacturers in this sector.

Growth Factor of the Market

Several factors are propelling the growth of the medical hemostatic agents market. One of the primary growth drivers is the increasing number of surgical procedures globally, which necessitates effective hemostatic solutions to prevent excessive bleeding during and after surgeries. Additionally, the rise in trauma cases due to accidents, sports injuries, and violent incidents also contributes to the demand for hemostatic agents. The aging population, which often requires surgical interventions for various health issues, further amplifies the market's expansion. Moreover, advancements in medical technologies, such as minimally invasive surgical techniques, are increasing the need for specialized hemostatic agents. Innovations in the formulation of hemostatic agents, particularly those that accelerate clot formation and enhance patient outcomes, also represent a crucial factor in the market's growth trajectory.

Key Highlights of the Market

• The market is forecasted to grow at a CAGR of 4.5% from 2022 to 2035.
• Increased surgical procedures are driving the demand for hemostatic agents.
• Trauma cases and chronic disease prevalence are significant contributors to market growth.
• Technological advancements in hemostatic products are enhancing their effectiveness and safety.
• The aging population is resulting in higher surgical intervention rates, boosting market demand.

By Product Type

Thrombin-Based Hemostats:

Thrombin-based hemostats are widely used in surgical settings due to their ability to promote rapid clotting. These agents work by converting fibrinogen to fibrin in the presence of thrombin, thereby facilitating the clotting process. Their effectiveness in controlling bleeding makes them a preferred choice in various medical applications, including orthopedic and cardiovascular surgeries. The thrombin-based hemostats market is projected to witness substantial growth, fueled by ongoing advancements in formulation and delivery systems that enhance their efficacy and reduce potential side effects. Moreover, the increasing incidence of surgeries requiring hemostatic support further bolsters the demand for thrombin-based options.

Gelatin-Based Hemostats:

Gelatin-based hemostatic agents are derived from natural sources and are known for their biocompatibility and safety profile. These agents are specifically formulated to absorb moisture and create a gel-like consistency, which aids in achieving hemostasis. Gelatin hemostats are particularly beneficial in minimally invasive surgeries due to their ease of use and rapid action. The rising adoption of gelatin-based products in various surgical procedures contributes to their market growth. Additionally, the versatility of these agents allows for their application in various medical fields, including general surgery and trauma care, enhancing their market reach.

Collagen-Based Hemostats:

Collagen-based hemostatic agents are another important category in the market, leveraging the natural properties of collagen to promote hemostasis. Collagen acts as a scaffold for platelet aggregation, significantly aiding in wound healing and clot formation. These agents are especially effective in surgical settings, where rapid hemostatic action is necessary, such as in orthopedic and neurosurgeries. The increasing preference for collagen-based hemostats can be attributed to their biocompatibility and effectiveness in controlling bleeding. Ongoing research and development efforts aimed at enhancing the performance and safety profile of collagen-based agents are expected to further drive their market penetration.

Oxidized Regenerated Cellulose-Based Hemostats:

Oxidized regenerated cellulose-based hemostatic agents are synthesized to achieve rapid hemostatic action while being fully absorbable by the body. These agents work by providing a physical matrix for clot formation, making them effective in controlling bleeding during surgical procedures. Their ability to integrate into the wound site and promote healing further enhances their clinical utility. The market for oxidized regenerated cellulose-based agents is anticipated to grow as more surgeons recognize their effectiveness and ease of use, particularly in complex surgical scenarios. The increasing focus on minimally invasive procedures is also expected to positively impact the adoption of these hemostats.

Combination Hemostats:

Combination hemostatic agents offer a synergistic approach to bleeding control by incorporating multiple hemostatic mechanisms in a single product. These agents typically combine thrombin, gelatin, and other components to enhance the overall hemostatic efficacy. Their versatility makes them suitable for use in diverse surgical environments, particularly where standard hemostatic agents may not suffice. The demand for combination hemostats is driven by their improved performance in complex surgical procedures and their ability to cater to various clinical needs. As the surgical landscape evolves towards more complex and diverse procedures, the adoption of combination hemostats is expected to rise significantly.

By Application

Trauma:

The trauma application segment is a crucial aspect of the medical hemostatic agents market, driven by the rising incidence of traumatic injuries globally. Hemostatic agents play a vital role in emergency medicine by controlling bleeding in trauma cases, which can significantly improve patient outcomes. The demand for effective trauma management solutions, including hemostatic agents, is growing as the awareness of immediate care in critical situations increases. Furthermore, advancements in pre-hospital care techniques and equipment are propelling the use of hemostatic agents in trauma applications, ensuring rapid and effective hemorrhage control.

Surgery:

Surgical procedures represent a significant market share for medical hemostatic agents, as controlling bleeding is paramount during operations. Whether in orthopedic, cardiovascular, or general surgeries, maintaining hemostasis is critical for patient safety and successful outcomes. The growing number of surgical procedures performed annually due to the aging population and rising prevalence of chronic diseases drives the demand for effective hemostatic solutions. As surgical techniques evolve, particularly with the trend towards minimally invasive surgeries, the need for specialized hemostatic agents that can function efficiently in these settings continues to grow.

Cardiology:

The cardiology segment utilizes hemostatic agents primarily to manage bleeding during cardiovascular interventions such as angioplasty and bypass surgeries. Given the delicate nature of cardiovascular procedures, the demand for effective hemostatic solutions is high. Hemostatic agents help reduce the risk of complications associated with bleeding, facilitating safer surgical practices. The increasing prevalence of cardiovascular diseases and the growing number of interventional procedures are key factors driving the adoption of hemostatic agents in this segment. Innovations in hemostatic technology tailored specifically for cardiology applications are expected to further enhance market growth.

Obstetrics & Gynecology:

In obstetrics and gynecology, hemostatic agents are critical in managing bleeding during childbirth and gynecological surgeries. The need for effective bleeding control in these settings is paramount, given the potential complications associated with excessive blood loss. The rising number of childbirths and gynecological procedures worldwide contributes to the growing demand for hemostatic agents. Additionally, the emphasis on enhancing maternal safety during childbirth and improving surgical outcomes in gynecology is further driving the market for these products. Innovations tailored to obstetric and gynecological applications are creating new opportunities within this segment.

Dentistry:

The dentistry application segment for hemostatic agents has seen increased growth as dental procedures often involve bleeding management. Hemostatic products are utilized in various dental surgeries, including extractions, implants, and periodontal surgeries, to ensure optimal outcomes. The expanding prevalence of dental diseases and the rising number of dental procedures performed globally are key factors contributing to the demand for hemostatic agents in this field. Moreover, advancements in dental technologies and materials are enhancing the effectiveness of hemostatic solutions, resulting in better patient experiences and outcomes.

By Distribution Channel

Hospitals:

Hospitals represent the largest distribution channel for medical hemostatic agents, as they are the primary settings where surgeries and trauma management occur. The demand for hemostatic agents in hospitals is driven by the increasing number of surgical procedures and emergency interventions performed daily. With surgical departments requiring reliable and effective hemostatic solutions, hospitals are major consumers of these products. The ongoing emphasis on improving patient outcomes and ensuring safety during procedures further solidifies the position of hospitals as a key distribution channel for hemostatic agents. As hospitals continue to adopt advanced technologies and practices, the demand for innovative hemostatic products is likely to increase.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have emerged as a growing distribution channel for medical hemostatic agents due to the rising popularity of outpatient procedures. These centers are designed to provide surgical services without the need for overnight hospitalization, which requires efficient management of bleeding during surgeries. As more patients opt for outpatient surgical options, the demand for effective hemostatic agents in ASCs is increasing. The convenience and cost-effectiveness of ASCs contribute to their appeal, further driving their adoption of hemostatic products. The increasing number of ASCs globally is expected to create substantial growth opportunities for manufacturers in this segment.

Specialty Clinics:

Specialty clinics play an essential role in the distribution of medical hemostatic agents, particularly for targeted procedures that require specialized expertise. These clinics often cater to specific medical fields such as orthopedics, cardiology, and dermatology, where hemostatic agents are essential for managing bleeding during procedures. The rising prevalence of chronic conditions and the need for specialized surgical interventions drive the demand for hemostatic solutions in specialty clinics. As the healthcare landscape evolves towards specialization, the importance of specialty clinics in the hemostatic agent market is likely to increase. The focus on patient-centric care and tailored treatment approaches further enhances the significance of this distribution channel.

Online Sales:

Online sales of medical hemostatic agents have gained traction as more healthcare professionals and institutions turn to e-commerce for procuring medical supplies. The convenience of online purchasing, along with the ability to compare products and prices, makes this channel increasingly popular among healthcare providers. Additionally, the COVID-19 pandemic accelerated the shift towards digital transactions, leading to a sustained increase in online sales. E-commerce platforms provide access to a wide range of hemostatic products, enabling healthcare providers to source the necessary agents quickly and efficiently. The continued growth of online sales is expected to create new opportunities for manufacturers and distributors, expanding the reach of their products to a broader audience.

By Ingredient Type

Gelatin:

Gelatin is a key ingredient in many hemostatic agents, valued for its biocompatibility and rapid action in promoting clot formation. Gelatin-based hemostatic agents are particularly effective in managing bleeding during surgical procedures due to their ability to absorb moisture and form a gel-like consistency that accelerates hemostasis. The increasing preference for gelatin-based options is driven by their safety profile and effectiveness, making them a popular choice among surgeons across various medical specialties. Additionally, ongoing research and development efforts aimed at enhancing gelatin formulations are expected to further strengthen their position in the market.

Collagen:

Collagen is another critical ingredient in the formulation of hemostatic agents, playing a vital role in wound healing and hemostasis. By providing a natural scaffold for platelet aggregation, collagen-based agents enhance clot formation and minimize bleeding during surgical procedures. The rising adoption of collagen in hemostatic applications is attributed to its excellent biocompatibility and effectiveness in various surgical settings. As more healthcare providers recognize the benefits of collagen-based products, the demand for these hemostatic agents is expected to grow significantly, particularly in areas such as orthopedics and cardiovascular surgeries.

Thrombin:

Thrombin is a crucial ingredient in several hemostatic agents, known for its ability to catalyze the conversion of fibrinogen to fibrin, thereby promoting clot formation. Thrombin-based hemostatic agents are widely used in surgical procedures where rapid hemostatic action is essential. The growing prevalence of surgical interventions and the increasing need for efficient hemostatic solutions are driving the demand for thrombin-containing products. Innovations in thrombin formulations, including recombinant options that reduce the risk of disease transmission, are expected to further enhance the market appeal of these agents, leading to increased adoption in clinical settings.

Oxidized Regenerated Cellulose:

Oxidized regenerated cellulose is a synthetic ingredient used in various hemostatic agents, known for its unique properties that promote hemostasis. This ingredient provides a physical barrier to bleeding while being absorbable by the body, making it suitable for use in a range of surgical applications. The demand for oxidized regenerated cellulose-based hemostatic agents is driven by their effectiveness in controlling bleeding, particularly in complicated surgical scenarios. As healthcare providers increasingly recognize the benefits of using oxidized regenerated cellulose, the market for these products is anticipated to grow, with continuous innovations enhancing their performance and usability.

Fibrin Sealant:

Fibrin sealants are advanced hemostatic agents that mimic the natural clotting process, providing a strong and effective means of controlling bleeding during surgical procedures. These products consist of a combination of fibrinogen and thrombin, which, when mixed, form a fibrin clot. The increasing adoption of fibrin sealants in various surgical specialties, including orthopedic and cardiovascular surgeries, is driving their market growth. The effectiveness of these sealants in achieving rapid hemostasis while promoting wound healing makes them highly sought after in clinical settings. Ongoing advancements in fibrin sealant formulations and delivery systems are expected to further enhance their applicability and performance, solidifying their position in the market.

By Region

The North American region holds the largest share of the medical hemostatic agents market, attributed to the high prevalence of chronic diseases, advanced healthcare infrastructure, and a significant number of surgical procedures conducted annually. The United States, being a leader in medical technology and innovation, fosters an environment conducive to the development and adoption of advanced hemostatic solutions. The market in North America is projected to grow at a CAGR of 4.2% during the forecast period, primarily driven by the increasing demand for effective bleeding control solutions in hospitals and surgical centers. The emphasis on improving patient outcomes and safety during procedures further enhances the growth prospects in this region.

In Europe, the medical hemostatic agents market is also witnessing significant growth, fueled by a rising aging population and an increase in surgical interventions across member countries. The European market benefits from a robust healthcare system and widespread adoption of advanced medical technologies. Additionally, the presence of key market players and ongoing research initiatives in the region contribute to market growth. The European market is anticipated to grow at a CAGR of 3.8%, driven by ongoing innovations and the increasing focus on effective wound care solutions. The demand for hemostatic agents in countries like Germany, France, and the UK is expected to remain high, reflecting the overall positive growth trajectory.

Opportunities

The medical hemostatic agents market presents several lucrative opportunities for growth and expansion, particularly in emerging markets where healthcare infrastructure is rapidly developing. Countries in Asia Pacific and Latin America are witnessing increasing investments in healthcare facilities and technology, leading to a rise in surgical procedures and, consequently, the demand for medical hemostatic agents. As healthcare providers in these regions become more aware of the benefits of effective bleeding control solutions, the adoption of hemostatic agents is expected to rise significantly. Moreover, the growing middle-class population in these areas is driving demand for better healthcare options, creating a favorable environment for the expansion of hemostatic product offerings.

Another significant opportunity lies in the continuous advancements in hemostatic product formulations and technologies. Ongoing research and development efforts aimed at improving the efficacy and safety of hemostatic agents are likely to yield innovative solutions that can address unmet clinical needs. For instance, the development of biologically active hemostatic agents that promote faster wound healing and reduce complications can attract a broader customer base. Companies that invest in R&D to create state-of-the-art hemostatic products are well-positioned to capitalize on market trends and establish themselves as leaders in this competitive landscape.

Threats

While the medical hemostatic agents market is poised for growth, it also faces certain threats that could impact its trajectory. One of the most significant threats is the increasing regulatory scrutiny and stringent compliance requirements imposed on the pharmaceutical and medical device industries. Companies operating in the hemostatic agents market must navigate complex regulations governing product safety, efficacy, and marketing, which can pose challenges in terms of time and cost. Additionally, any delays in regulatory approvals or changes in regulations can hinder market entry for new products, limiting growth opportunities for manufacturers.

Moreover, the presence of alternative bleeding control methods and products can pose a challenge to the hemostatic agents market. Emerging technologies, such as mechanical devices and bio-adhesive solutions, offer competing options for managing bleeding, which may impact the demand for traditional hemostatic agents. As healthcare providers seek innovative and cost-effective solutions, it becomes essential for hemostatic agents to demonstrate clear advantages over these alternatives. Companies that fail to adapt to changing market dynamics or innovate accordingly may find it increasingly difficult to maintain market share.

Competitor Outlook

• Johnson & Johnson.
• Medtronic.
• Baxter International Inc.
• Hemostatic Technologies, Inc.
• CSL Behring.
• Pfizer Inc.
• Smith & Nephew plc.
• Integra LifeSciences Corporation.
• Ethicon, Inc.
• Sanofi S.A.
• ConvaTec Group PLC.
• Hemostasis, LLC.
• Grifols S.A.
• Terumo Corporation.
• 3M Company.

The competitive landscape of the medical hemostatic agents market is characterized by a diverse range of key players that are actively focusing on product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position. Major companies such as Johnson & Johnson and Medtronic lead the market due to their extensive product portfolios and strong distribution networks. These companies are continually investing in research and development to introduce advanced hemostatic solutions that cater to the evolving needs of healthcare providers and patients alike. Additionally, collaborations with healthcare institutions and participation in clinical studies are common strategies employed by these companies to enhance the visibility and credibility of their products.

Furthermore, firms like Baxter International and CSL Behring are leveraging their expertise in blood products and biopharmaceuticals to develop specialized hemostatic agents that offer unique benefits to patients undergoing surgical procedures. This focus on niche markets allows them to differentiate their offerings and capture a larger share of the market. The growing trend of personalized medicine is also prompting these companies to explore tailored hemostatic solutions that address specific patient needs, thus enhancing their competitive edge.

Emerging players such as Hemostatic Technologies and Grifols S.A. are also gaining traction in the market by offering innovative products that challenge established players. These companies often focus on developing targeted hemostatic agents that are particularly effective in specific applications, such as trauma or cardiac surgery. Their agility and ability to respond quickly to market demands enable them to carve out a niche for themselves. Overall, the dynamic nature of the competitive landscape in the medical hemostatic agents market necessitates continuous innovation and adaptation to maintain relevance and market share.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 3M Company.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 CSL Behring.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Grifols S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Ethicon, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Hemostasis, LLC.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 ConvaTec Group PLC.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Smith & Nephew plc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Terumo Corporation.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Baxter International Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hemostatic Technologies, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Integra LifeSciences Corporation.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Medical Hemostatic Agents Market, By Application
    • 6.1.1 Trauma
    • 6.1.2 Surgery
    • 6.1.3 Cardiology
    • 6.1.4 Obstetrics & Gynecology
    • 6.1.5 Dentistry
  • 6.2 Medical Hemostatic Agents Market, By Product Type
    • 6.2.1 Thrombin-Based Hemostats
    • 6.2.2 Gelatin-Based Hemostats
    • 6.2.3 Collagen-Based Hemostats
    • 6.2.4 Oxidized Regenerated Cellulose-Based Hemostats
    • 6.2.5 Combination Hemostats
  • 6.3 Medical Hemostatic Agents Market, By Ingredient Type
    • 6.3.1 Gelatin
    • 6.3.2 Collagen
    • 6.3.3 Thrombin
    • 6.3.4 Oxidized Regenerated Cellulose
    • 6.3.5 Fibrin Sealant
  • 6.4 Medical Hemostatic Agents Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Medical Hemostatic Agents Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Medical Hemostatic Agents market is categorized based on

By Product Type

• Thrombin-Based Hemostats
• Gelatin-Based Hemostats
• Collagen-Based Hemostats
• Oxidized Regenerated Cellulose-Based Hemostats
• Combination Hemostats

By Application

• Trauma
• Surgery
• Cardiology
• Obstetrics & Gynecology
• Dentistry

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales

By Ingredient Type

• Gelatin
• Collagen
• Thrombin
• Oxidized Regenerated Cellulose
• Fibrin Sealant

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson.
• Medtronic.
• Baxter International Inc.
• Hemostatic Technologies, Inc.
• CSL Behring.
• Pfizer Inc.
• Smith & Nephew plc.
• Integra LifeSciences Corporation.
• Ethicon, Inc.
• Sanofi S.A.
• ConvaTec Group PLC.
• Hemostasis, LLC.
• Grifols S.A.
• Terumo Corporation.
• 3M Company.